References of "Mulder, H"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLong-term efficacy of risedronate: a 5-year placebo-controlled clinical experience
Sorensen, O. H.; Crawford, G. M.; Mulder, H. et al

in BONE (2003), 32(2), 120-126

Limited placebo-controlled data are available to assess the long-term fracture efficacy of bisphosphonates. In order to determine the effects of 5 years of risedronate treatment, we extended a 3-year ... [more ▼]

Limited placebo-controlled data are available to assess the long-term fracture efficacy of bisphosphonates. In order to determine the effects of 5 years of risedronate treatment, we extended a 3-year, placebo-controlled vertebral fracture study in osteoporotic women for an additional 2 years; women who entered the extension study continued to receive 5 mg risedronate or placebo according to the original randomization, with maintenance of blinding. End points included vertebral and nonvertebral fracture assessments, bone mineral density measurements, and changes in biochemical markers of bone turnover. A total of 265 women (placebo, 130; 5 mg risedronate, 135) entered the study extension and 220 (83%) completed the additional 2 years. Fracture results observed in the study extension were consistent with those observed in the first 3 years. The risk of new vertebral fractures was significantly reduced with risedronate treatment in years 4 and 5 by 59% (95% confidence interval, 19 to 79%, P = 0.01) compared with a 49% reduction in the first 3 years. Rapid and significant decreases in markers of bone turnover observed in the first 3 years were similarly maintained in the next 2 years of treatment. Increases in spine and hip bone mineral density that occurred in the risedronate group during the first 3 years were maintained or increased with a further 2 years of treatment. The mean increase from baseline in lumbar spine BMD over 5 years was 9.3% (P < 0.001). This study demonstrates that the effects of risedronate over 3 years on vertebral fracture and BMD are maintained with a further 2 years of treatment. (C) 2003 Elsevier Science (USA). All rights reserved. [less ▲]

Detailed reference viewed: 35 (4 ULg)
Full Text
Peer Reviewed
See detailSustained fracture risk reduction over 5 years with risedronate therapy
Watts, NB; Brown, J; Hosking, D et al

in Journal of Bone and Mineral Research (2001), 16(S1), 217

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailSustained fracture benefit with five years of risedronate in postmenopausal women
Hosking, D; Sorensen, OD; Mulder, H et al

in BONE (2001), S28

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailComparative double-blind multicenter study of the efficacy of tiludronate and etidronate in Paget's disease of bone
Roux, C; Gennari, C; Farrerons, J et al

in BONE (1995), 16(S1), 503

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailComparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
Roux, C.; Gennari, C.; Farrerons, J. et al

in Arthritis and Rheumatism (1995), 38(6), 851-8

OBJECTIVE: To compare the efficacy and safety of tiludronate and etidronate at the same dosage (400 mg/day) for the treatment of active Paget's disease of bone. METHODS: We studied 234 patients with ... [more ▼]

OBJECTIVE: To compare the efficacy and safety of tiludronate and etidronate at the same dosage (400 mg/day) for the treatment of active Paget's disease of bone. METHODS: We studied 234 patients with radiologic lesions characteristic of Paget's disease of bone and serum alkaline phosphatase (AP) concentrations at least twice the upper limit of normal, in a prospective, randomized, double-blind, multicenter clinical trial lasting 6 months. Patients were randomly allocated into 1 of 3 treatment groups: tiludronate for 3 months followed by placebo for 3 months, tiludronate for 6 months, or etidronate for 6 months. Serum AP levels and urinary hydroxyproline excretion were measured at baseline and after 3 months and 6 months. Patients with a reduction of at least 50% in the serum AP concentration were considered to be responders. RESULTS: After 3 months, the proportion of responders was higher in the tiludronate group (57.4%) than in the etidronate group (13.9%) (P < 0.0001). In the etidronate group, this percentage was lower among patients who had received previous treatment with a bisphosphonate (2.3%) than among those who had not (28.6%) (P < 0.01). Previous bisphosphonate treatment was not associated with response in the tiludronate group. After 6 months, the proportion of responders did not differ between the 2 tiludronate groups (60.3% and 70.1%), but was lower in the etidronate group (25.3%) (P < 0.0001). There was a higher proportion of patients with treatment-resistant disease (< 25% reduction of serum AP) in the etidronate group (51.9%) than in the tiludronate 3-month group (17.9%) or the tiludronate 6-month group (19.5%) (P < 0.0001). Gastrointestinal disturbances were more common, and occurred earlier, with tiludronate, but they were mostly mild, requiring no treatment. CONCLUSION: Tiludronate at 400 mg/day for 3 months or 6 months is more effective than the same dosage of etidronate for 6 months in the treatment of Paget's disease. [less ▲]

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailTiludronate et étidronate au cours de la maladie de Paget: étude comparative prospective, multicentrique en double aveugle
Roux, C; Gennari, C; Farrerons, I et al

in Revue du Rhumatisme (1994), 10

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailTiludronate and etidronate in Paget's disease of bone: a comparative prospective double-blind multicenter study
Roux, C; Gennari, C; Farrenons, J et al

in Journal of Bone and Mineral Research (1994), 9(S1), 296

Detailed reference viewed: 7 (1 ULg)